Short Interest in Bone Biologics Co. (NASDAQ:BBLG) Increases By 562.5%

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totalling 5,300 shares, an increase of 562.5% from the June 30th total of 800 shares. Approximately 1.0% of the company’s stock are sold short. Based on an average trading volume of 835,900 shares, the short-interest ratio is currently 0.0 days.

Bone Biologics Price Performance

Shares of NASDAQ BBLG traded down $0.10 during mid-day trading on Friday, reaching $1.99. The company had a trading volume of 459,317 shares, compared to its average volume of 2,649,135. The stock has a fifty day moving average of $1.40 and a two-hundred day moving average of $2.20. Bone Biologics has a 12-month low of $1.00 and a 12-month high of $11.76.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($1.31) EPS for the quarter, beating the consensus estimate of ($7.60) by $6.29. Equities research analysts predict that Bone Biologics will post -5.32 earnings per share for the current fiscal year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.